Myocardial enzyme activity inhibition

"Myocardial enzyme activity inhibition" is not a specific biological molecule, receptor, or enzyme, but rather describes a physiological or pharmacological effect on the suite of enzymes found within cardiac tissue. In a clinical and toxicological context, this term often refers to the reduction in the activity of enzymes such as creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), and aspartate aminotransferase (AST), which are traditionally used as biomarkers for myocardial injury or infarction (StatPearls, 2023; NIH, 2022). While certain cardioprotective agents may aim to stabilize cell membranes and reduce the leakage of these enzymes into the systemic circulation, the phrase "myocardial enzyme activity inhibition" does not represent a single therapeutic target used in drug discovery. Instead, it typically appears in research discussing the adverse effects of toxins or the protective effects of antioxidants and drugs against myocardial damage (PubMed, 2021). Because it lacks a specific molecular identity or a defined binding site for pharmacological agents, it is classified as an incorrect or overly broad target designation for drug development purposes.

Other names

Inhibition of cardiac enzymesMyocardial enzyme suppression

Not applicable as this is a physiological effect or clinical observation rather than a specific molecular target.